



Board of Pharmacy

e-News September 2025

Fee Change Notice - Effective September 30, 2025

Several license application fees will change effective September 30, 2025. These changes were authorized by the Ohio General Assembly with the passage of the state's biennial budget (H.B. 96, 136th General Assembly). Please review this email to understand how these changes may impact your license/registration.

Pharmacy Technician	
Pharmacy Technician Trainee	\$40.00
Registered Pharmacy Technician	\$65.00
Certified Pharmacy Technician	\$65.00
Terminal Distributors	
Category 2 (in-state)	\$360.00
Category 3 (in-state)	\$460.00
Reduced Fee (in-state EMS satellites, veterinary clinics, and sole prescriber-owned entities)	\$160.00
Non-Resident Pharmacies	\$500.00
Drug Distributors	
Category 2 (in-state)	\$1,900.00
Category 3 (in-state)	\$2,000.00
Category 2 or 3 (non-resident)	\$2,000.00
Change of Responsible Person (New Fee)	
Terminal Distributor and Drug Distributor – All Types	\$15.00

The Ohio Board of Pharmacy will be taking the following actions over the next few months to implement the fee changes:

- All Terminal – Non-Resident Pharmacy license types (Category 2, Category 3, and Limited Category 2) will be consolidated into a single license type named “**Terminal – Non-Resident Pharmacy**”.
- Drug Distributors located out of the state of Ohio (nonresident) will receive an updated sub-category with an indication of nonresident in the name. Example: a sub-category of “MF – Manufacturer” for a licensee in Tennessee will receive a new sub-category of “**MF – Manufacturer (nonresident)**”.
- Change of Responsible Person Service Requests in [eLicense](#) will be re-directed to a payment page for fee collection purposes. The change request will not be considered

submitted and notified as required in [OAC 4729:5-2-01](#) and [OAC 4729:6-2-01](#) until payment has been successfully submitted.

All application and fee payments must be submitted electronically via the [eLicense Ohio system](#). The Board does not accept check payments to the Board office. Valid payment methods for all license fees include Visa, MasterCard, and Discover. The Board does not accept electronic checks or American Express.

**The term “distributor of dangerous drugs” or “drug distributor” refers to the following license types: manufacturer of dangerous drugs, outsourcing facility, third-party logistics provider, repackager of dangerous drugs, and wholesale distributor of dangerous drugs (includes broker and virtual wholesaler).*

Rules for Stakeholder Comment - Impaired Licensees, Registrants, and Probation

Date Issued: 9/30/2025
Comments Due: 10/27/2025

In accordance with Chapter 119. of the Revised Code, the Ohio Board of Pharmacy proposes the adoption of the following rules:

- **4729:4-1-01: Definitions - Impaired licensees, registrants, and probation. (AMEND)**
- **4729:4-1-02: Applicability. (AMEND)**
- **4729:4-1-04: Monitoring Contracts. (AMEND)**
- **4729:4-1-05: Probation. (AMEND)**
- **4729:4-1-07: Summary suspension of a licensee or registrant. (AMEND)**
- **4729:4-1-09: Terms while under suspension (AMEND)**

To view the proposed rules, please visit www.pharmacy.ohio.gov/licenseesregistrantsprobation.

Comments on the proposed rules will be accepted until close of business on **Monday, October 27, 2025.**

Please send all comments to the following email address:
RuleComments@pharmacy.ohio.gov.

Counterfeit Versions of Botox Found in Multiple Stores

FDA is alerting health care professionals and consumers that unsafe counterfeit versions of Botox (botulinum toxin) have been found in multiple states and administered to consumers for cosmetic purposes.

FDA is aware of adverse events, including hospitalizations, linked to the counterfeit Botox. Symptoms included blurred or double vision, difficulty swallowing, dry mouth, constipation, incontinence, shortness of breath, weakness, and difficulty lifting one’s head following injection of these products. These symptoms are similar to those seen when [botulinum toxin](#) spreads to other parts of the body.

FDA-approved [Botox](#) is available in 100- and 200-unit vials. FDA-approved [Botox Cosmetic](#) is available in 50- and 100-unit vials. The FDA-approved Botox products display the active ingredient as “OnabotulinumtoxinA” on the outer carton and vial.

The product description on the outer carton is one of the following:

- “BOTOX® COSMETIC / onabotulinumtoxinA / for injection”
- “OnabotulinumtoxinA / BOTOX® / for injection”

The manufacturer identified on the outer carton is one of the following:

- “Allergan Aesthetics / An AbbVie Company”
- “Allergan”
- “abbvie”

For more information and to view images of authentic, FDA-approved Botox products, visit: <https://www.fda.gov/drugs/drug-safety-and-availability/counterfeit-version-botox-found-multiple-states>.

Letters of Interest for the Ohio Department of Medicaid's Drug Utilization Review Committee

The Ohio Department of Medicaid (ODM) is requesting Letters of Interest for the purpose of identifying two (2) qualified pharmacists to serve on ODM's Drug Utilization Review (DUR) Committee. Ohio's DUR program is a provider-oriented, educational outreach program designed to alert physicians, pharmacists, and Medicaid recipients to inappropriate or medically unnecessary pharmacological care. The purpose of the program is to safeguard the health of Medicaid recipients, to assess the appropriateness of drug therapy, and to reduce the frequency of fraud, abuse, and overuse of prescribed drugs. State Medicaid programs are required to perform DUR functions under the Social Security Act, § 1927(g) and Ohio Administrative Code (OAC) Section 5160-9-04. The rate of compensation under each contract will be \$150.00 per meeting for up to 12 meetings per State Fiscal Year.

Submissions must be submitted in OhioBuys to be considered. For more information and to submit a letter of interest, visit:

https://ohiobuys.ohio.gov/page.aspx/en/bpm/process_manage_extranet/46980.

National Prescription Drug Takeback Day

On Saturday, October 25, the Drug Enforcement Administration will host DEA's National Prescription Drug Take Back Day at locations across the country. DEA and its partners will collect tablets, capsules, patches, and other solid forms of prescription drugs.

National Prescription Drug Take Back Day aims to provide a safe, convenient, and responsible means of disposing of prescription drugs, while also educating the public about the potential for abuse of medications. For more information, please visit: www.DEATakeBack.com.

The Board has also published several resources regarding the disposal of drugs in Ohio. The resources can be found on the Board's website or by following this link:

www.pharmacy.ohio.gov/disposal.

Be Vigilant - Watch Out for Scammers!

BOARD STAFF DO NOT ASK FOR MONEY OVER THE PHONE OR VIA EMAIL TO RESOLVE PENDING INVESTIGATIONS. WHEN IN DOUBT, PLEASE CONTACT THE BOARD IF YOU BELIEVE YOU ARE THE TARGET OF A SCAM.

The Ohio Board of Pharmacy continues to learn that licensees are being targeted by scammers

who claim to work for various governmental agencies (Board of Pharmacy, DEA, FBI, Department of Justice, etc.) to obtain money from the target. The Board strongly encourages licensees to be alert to avoid scammers.

Scammers may try to initiate contact via phone calls, emails, faxes, and letters purporting to originate from various state and federal agencies that include allegations of drug trafficking and threats of suspension against the target's license.

Board of Pharmacy investigators will not ask for fine payment or personal/sensitive information over the phone and will never contact licensees via fax. As a reminder, administrative fines issued by the Board are not paid via gift cards or cryptocurrency. If the Board of Pharmacy is conducting an investigation and that individual faces action against their license, they will receive an official notice of opportunity for a hearing either via certified mail, personal service, or electronic registered mail.

If you are contacted by a scammer, please report this information using the Board's online complaint form: www.pharmacy.ohio.gov/complaint. Additionally, reports should be made to your local law enforcement agency.

If you receive any suspicious calls or correspondence purporting to be from the Board of Pharmacy, we encourage you to call (614-466-4143) or email (contact@pharmacy.ohio.gov) the Board to confirm its legitimacy.



People call, text, and chat the 988 Lifeline to talk about a lot of emotional needs—not just thoughts of suicide. Whatever your reason, the #988Lifeline is there to help. There is hope.



Ohio Board of Pharmacy
Mike DeWine, Governor | Steven W. Schierholt, Executive Director

Ohio Board of Pharmacy | 77 S. High St 17th Floor | Columbus, OH 43215 US

[Unsubscribe](#) | [Constant Contact Data Notice](#)